Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study will test an investigational vaccine, called DRibbles, for the treatment of
non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine
will cause an immune responses against proteins contained in the DRibble vaccine and the
protein antigens targeted by this strong immune response will include common antigens shared
by both the vaccine and the patient's tumor.
Phase:
Phase 2
Details
Lead Sponsor:
UbiVac
Collaborators:
Louisiana State University Health Sciences Center in New Orleans Mayo Clinic National Cancer Institute (NCI) Providence Cancer Center, Earle A. Chiles Research Institute Providence Health & Services